Malignant Pleural Mesothelioma
📧 Sign up to get email alerts when something new happens for Malignant Pleural Mesothelioma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors [Phase 1]
Phase 1 study of an oral TEAD inhibitor from Ikena Oncology in adults with advanced solid tumors has been terminated. The trial included pat…
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: Alvopem® (Pemetrexed) Safety Assessment
Safety data from completed trials of Alvopem (pemetrexed) have been assessed and results are now posted.
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma [Phase 1, Phase 2]
This update reports results from a Phase 1/2 study of pembrolizumab with or without the mesothelin-targeting antibody-drug conjugate anetuma…
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy [Phase 2]
Phase 2 clinical trial update evaluating the Galinpepimut-S WT-1 peptide vaccine in Malignant Pleural Mesothelioma after combined modality t…
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma [Phase 2]
A Phase 2 clinical trial evaluating switch-maintenance gemcitabine after first-line chemotherapy in malignant pleural mesothelioma has compl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma [Phase 1]
This clinical trial update documents a Phase 1 window-of-opportunity study of pembrolizumab in patients with resectable malignant pleural me…
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma
The clinical trial NCT02613312 evaluating chemotherapy followed by surgery and neoadjuvant hemithoracic IMRT for malignant pleural mesotheli…
-
CLINICAL_TRIALS trial_result · 2024-07-01Clinical Trial Update: SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II [Phase 2]
Phase II ORIGIN trial (SAKK 17/18) evaluating first-line gemcitabine with atezolizumab in malignant pleural mesothelioma and non-small cell …
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) [Phase 1]
Phase 1 study of pembrolizumab in combination with cisplatin and pemetrexed for advanced malignant pleural mesothelioma has completed, with …
-
CLINICAL_TRIALS trial_result · 2024-03-05Clinical Trial Update: Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma [Phase 1]
Phase 1 trial evaluating atezolizumab with pemetrexed disodium and cisplatin, followed by surgery with or without radiation, for Stage I–III…
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants [Phase 2]
Phase 2 window-of-opportunity trial of defactinib in surgically resectable malignant pleural mesothelioma was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2024-01-26Clinical Trial Update: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma [Phase 1, Phase 2]
A clinical trial update for RSO-021 in malignant pleural effusion due to advanced/metastatic solid tumors including mesothelioma across Phas…
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma [Phase 2]
Phase II clinical trial update for PF-03446962 in advanced malignant pleural mesothelioma has completed.
-
CLINICAL_TRIALS trial_result · 2023-05-31Clinical Trial Update: Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas [Phase 1, Phase 2]
Phase 1/2 trial investigating oral decitabine with tetrahydrouridine as epigenetic priming to enhance pembrolizumab in inoperable/unresectab…
-
CLINICAL_TRIALS trial_result · 2023-02-01Clinical Trial Update: Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma [Phase 2]
Phase 2 trial of transarterial chemoperfusion using cisplatin, methotrexate, and gemcitabine for unresectable pleural mesothelioma has compl…
-
CLINICAL_TRIALS trial_result · 2022-11-07Clinical Trial Update: Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM [Phase 2]
Phase 2 clinical trial evaluating pleurectomy/decortication with or without chemotherapy in early-stage malignant pleural mesothelioma.
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma [Phase 2]
Phase 2 trial update evaluating amatuximab (MORAb-009) for malignant pleural mesothelioma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-06-16Clinical Trial Update: MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma [Phase 2]
Phase 2 clinical trial update evaluating MTG201 plus nivolumab for relapsed malignant pleural mesothelioma.
-
CLINICAL_TRIALS trial_result · 2022-02-07Clinical Trial Update: PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma [Phase 3]
Phase 3 trial comparing Pembrolizumab immunotherapy to standard chemotherapy in advanced malignant pleural mesothelioma has completed with r…
-
CLINICAL_TRIALS trial_result · 2022-01-13Clinical Trial Update: MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma [Phase 2]
Phase 2 trial updates on MEDI4736 (durvalumab) alone or with tremelimumab in surgically resectable malignant pleural mesothelioma have compl…
-
CLINICAL_TRIALS trial_result · 2021-12-09Clinical Trial Update: Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent [Phase 2]
Phase 2 trial evaluating nintedanib in recurrent malignant pleural mesothelioma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-10-01Clinical Trial Update: A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma [Phase 1, Phase 2]
Phase 1/2 trial investigating BBI608 with pemetrexed and cisplatin in malignant pleural mesothelioma and non-small cell lung cancer has comp…
-
CLINICAL_TRIALS trial_result · 2021-09-29Clinical Trial Update: Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating intracavitary cisplatin-fibrin localized chemotherapy after pleurectomy/decortication or extrapleural …
-
CLINICAL_TRIALS trial_result · 2021-07-20Clinical Trial Update: Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) [Phase 1, Phase 2]
Phase I/II trial evaluating CBP501 in combination with pemetrexed and cisplatin for malignant pleural mesothelioma; study completed with pos…
-
CLINICAL_TRIALS trial_result · 2021-07-14Clinical Trial Update: Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. [Phase 2]
Phase 2 trial update of lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma.